About RISC-loading complex subunit TARBP2
RISC-loading complex subunit TARBP2 (TARBP2) is a protein
from Homo sapiens identified by UniProt accession
Q15633, 366 residues long.
MolForge cross-references it against 0 known binders and
124 disease associations.
Target properties
| Protein name | RISC-loading complex subunit TARBP2 |
| UniProt accession | Q15633 |
| Gene | TARBP2 |
| Organism | Homo sapiens |
| Length | 366 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (124)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.34
- hepatocellular carcinoma · score 0.10
- neoplasm · score 0.09
- adrenal cortex carcinoma · score 0.09
- azoospermia · score 0.08
- viral disease · score 0.08
- body mass index · score 0.07
- diffuse large B-cell lymphoma · score 0.07
- male infertility with teratozoospermia due to single gene mutation · score 0.06
- partial chromosome Y deletion · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15633-F1 | alphafold | PREDICTED | 74.68 | — |
Amino-acid sequence (366 residues)
MSEEEQGSGT TTGCGLPSIE QMLAANPGKT PISLLQEYGT RIGKTPVYDL LKAEGQAHQP NFTFRVTVGD TSCTGQGPSK KAAKHKAAEV ALKHLKGGSM LEPALEDSSS FSPLDSSLPE DIPVFTAAAA ATPVPSVVLT RSPPMELQPP VSPQQSECNP VGALQELVVQ KGWRLPEYTV TQESGPAHRK EFTMTCRVER FIEIGSGTSK KLAKRNAAAK MLLRVHTVPL DARDGNEVEP DDDHFSIGVG SRLDGLRNRG PGCTWDSLRN SVGEKILSLR SCSLGSLGAL GPACCRVLSE LSEEQAFHVS YLDIEELSLS GLCQCLVELS TQPATVCHGS ATTREAARGE AARRALQYLK IMAGSK
Explore RISC-loading complex subunit TARBP2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets